Wecome Pharmaceutical Co Ltd

Range Technology plans to contribute 1 billion yuan of its own funds to invest in Xiamen Shidai Shenyuan Venture Capital Fund Partnership, a limited partnership. The fund has a total committed size of 4.90001 billion yuan, with Range Technology holding a 20.4081 percent stake. The fund will focus on frontier technology areas such as artificial intelligence and embodied intelligence. Bestechnic plans to repurchase shares worth 50 million to 100 million yuan, at a price not exceeding 150 yuan per share, for employee stock ownership plans or equity incentives. CATL's wholly owned subsidiary Ningbo Wending plans to participate as a limited partner in Xiamen Shidai Yiyuan Venture Capital Fund Partnership, with a committed contribution of 1.12 billion yuan and a 19.4175 percent stake in the fund. The company's controlling shareholder Xiamen Ruiting will also participate in the fund as a limited partner, making this investment a related-party co-investment. Hangcha Group plans to issue convertible bonds to raise no more than 2.259 billion yuan, with a term of six years, for a forklift robot smart factory project, a new energy forklift expansion project, a forklift robot and logistics robot research and development project, and to supplement working capital. Weikang Pharmaceutical has received an approval notice from the National Medical Products Administration for a supplementary application for clinical trials of its Huangjia Ruangan Granules, agreeing to conduct a Phase III clinical trial for liver fibrosis caused by chronic hepatitis B virus infection.

Weikang Pharmaceutical announced that the company recently received the approval notice for the supplementary application of Jinqiancao Capsule issued by the National Medical Products Administration. This approval involves changes to the safety-related content in the drug's package insert and the excipients in the formulation, and also approves the addition of gelatin hollow capsules from Zhejiang Weikang Oujiang Capsule Co., Ltd. for use in this drug. In the first quarter of 2026, Weikang Pharmaceutical achieved revenue of 69.66 million yuan and a net profit attributable to the parent company of 1.74 million yuan.